9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
7 hedge funds and large institutions have $165K invested in 9 Meters Biopharma in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
133% more funds holding
Funds holding: 3 → 7 (+4)
87% less capital invested
Capital invested by funds: $1.25M → $165K (-$1.09M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$36.5K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$31.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$1.22M |
| 2 |
Goldman Sachs
New York
|
-$5.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$580 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $44K | +$36.5K | +126 | New |
|
|
RJFSA
2
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $38K | +$31.6K | +109 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $29K | +$24.4K | +84 | New |
|
|
4
Goldman Sachs
New York
| $28K | -$5.8K | -20 | -20% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $22K | +$18.6K | +64 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $3K | +$2.9K | +10 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1K | -$580 | -2 | -50% |
|
|
GAM
8
Gotham Asset Management
New York
| – | -$1.22M | -42 | Closed |
|
NMTR Hedge Fund Activity: Q4 2016 in Review
7 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q4 2016, worth a combined $165K — down 87% from $1.25M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NMTR positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $36.5K. The largest seller was Gotham Asset Management, exiting entirely with an estimated $1.22M sold.
- 7 institutional investors held 9 Meters Biopharma (NMTR) as of Q4 2016, up from 3 in Q3 2016.
- Funds reported $165K of 9 Meters Biopharma stock for Q4 2016, down 87% quarter-over-quarter.
- 5 funds opened new 9 Meters Biopharma positions in Q4 2016 and 1 closed out, a net change of +4 holders.
- The largest 9 Meters Biopharma buyer in Q4 2016 was Virtu KCG Holdings, an estimated $36.5K added.
- The largest 9 Meters Biopharma seller in Q4 2016 was Gotham Asset Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q4 2016.